What does APOTHEEK JOHAN COPPENS do?

APOTHEEK JOHAN COPPENS is a pharmacy in Gent. Private Limited, started on 14 December 2007, 1 establishment.

What is the address of APOTHEEK JOHAN COPPENS?

The registered office of APOTHEEK JOHAN COPPENS is located at Antwerpsesteenweg 100, 9000 Gent.

Is APOTHEEK JOHAN COPPENS still active?

Yes. According to the CBE (30 October 2026) APOTHEEK JOHAN COPPENS is active, legal situation “Normale toestand”, started on 14 December 2007.

Is APOTHEEK JOHAN COPPENS registered on Peppol?

Yes, APOTHEEK JOHAN COPPENS is registered on the Peppol network with ID 0208:0894208059.

What is the enterprise number of APOTHEEK JOHAN COPPENS?

The enterprise number of APOTHEEK JOHAN COPPENS is BE0894208059.

When was APOTHEEK JOHAN COPPENS founded?

APOTHEEK JOHAN COPPENS was founded on 14 December 2007.

Who are the directors of APOTHEEK JOHAN COPPENS?

According to the 2025 annual accounts, the directors of APOTHEEK JOHAN COPPENS are: Johan COPPENS, BIMACON BV.

Is APOTHEEK JOHAN COPPENS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 December 2007; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did APOTHEEK JOHAN COPPENS make in 2025?

APOTHEEK JOHAN COPPENS recorded a loss after taxes of € 41,755 in financial year 2025.

What is the revenue of APOTHEEK JOHAN COPPENS?

As a small company, APOTHEEK JOHAN COPPENS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 83,211.

APOTHEEK JOHAN COPPENS (Private Limited) - Gent

Dossier APOTHEEK JOHAN COPPENS, printed on 30 October 2026 from databakkes.be/en/0894208059/apotheek-johan-coppens. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 35 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

APOTHEEK JOHAN COPPENS from Gent, company number BE0894208059, closed financial year 2025 with a result of € -41,755 after tax. For that financial year APOTHEEK JOHAN COPPENS recorded a gross margin of € 83,211 and equity of € 10,675. Compared with financial year 2024, the result moved from € -25,696 to € -41,755. The company made a loss. The buffer shrank hard: equity is 80 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Shrank hard

€ 10,675

▼ 80% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -41,755

▼ 62 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 32,202

▼ 23% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -67,325.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost

€ 116,415

▲ 50% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,367

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 10,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 60,092

▲ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 15,633

▲ 73% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 148,792 Gross margin 2022: € 148,792 First fiscal year in the series	€ 111,754 Gross margin 2023: € 111,754 ▼ 25% vs 2022 (€ 148,792) Unfavourable step	€ 60,747 Gross margin 2024: € 60,747 ▼ 46% vs 2023 (€ 111,754) Unfavourable step	€ 83,211 Gross margin 2025: € 83,211 ▲ 37% vs 2024 (€ 60,747) Favourable step	▲ 37%
Profit after taxes	€ 50,818 Profit after taxes 2022: € 50,818 First fiscal year in the series	€ 23,526 Profit after taxes 2023: € 23,526 ▼ 54% vs 2022 (€ 50,818) Unfavourable step	€ -25,696 Profit after taxes 2024: € -25,696 ▼ € 49,222 vs 2023 (€ 23,526) Unfavourable step	€ -41,755 Profit after taxes 2025: € -41,755 ▼ € 16,059 vs 2024 (€ -25,696) Unfavourable step	▼ € 16,059
Equity	€ 65,100 Equity 2022: € 65,100 First fiscal year in the series	€ 78,126 Equity 2023: € 78,126 ▲ 20% vs 2022 (€ 65,100) Favourable step	€ 52,430 Equity 2024: € 52,430 ▼ 33% vs 2023 (€ 78,126) Unfavourable step	€ 10,675 Equity 2025: € 10,675 ▼ 80% vs 2024 (€ 52,430) Unfavourable step	▼ 80%
Total debts	€ 153,944 Total debts 2022: € 153,944 First fiscal year in the series	€ 126,931 Total debts 2023: € 126,931 ▼ 18% vs 2022 (€ 153,944) Favourable step	€ 140,542 Total debts 2024: € 140,542 ▲ 11% vs 2023 (€ 126,931) Unfavourable step	€ 238,244 Total debts 2025: € 238,244 ▲ 70% vs 2024 (€ 140,542) Unfavourable step	▲ 70%
Cash	€ 81,121 Cash 2022: € 81,121 First fiscal year in the series	€ 46,001 Cash 2023: € 46,001 ▼ 43% vs 2022 (€ 81,121) Unfavourable step	€ 41,644 Cash 2024: € 41,644 ▼ 9% vs 2023 (€ 46,001) Unfavourable step	€ 32,202 Cash 2025: € 32,202 ▼ 23% vs 2024 (€ 41,644) Unfavourable step	▼ 23%
Retained profit	€ -12,900 Retained profit 2022: € -12,900 First fiscal year in the series	€ 126 Retained profit 2023: € 126 ▲ € 13,026 vs 2022 (€ -12,900) Favourable step	€ -25,570 Retained profit 2024: € -25,570 ▼ € 25,696 vs 2023 (€ 126) Unfavourable step	€ -67,325 Retained profit 2025: € -67,325 ▼ € 41,755 vs 2024 (€ -25,570) Unfavourable step	▼ € 41,755
Dividend	€ 44,690 Dividend 2022: € 44,690 First fiscal year in the series	€ 10,500 Dividend 2023: € 10,500 ▼ 77% vs 2022 (€ 44,690) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 10,500) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 10,000 Bank debt 2022: € 10,000 First fiscal year in the series	€ 10,000 Bank debt 2023: € 10,000 Unchanged (€ 10,000) Unchanged	€ 10,000 Bank debt 2024: € 10,000 Unchanged (€ 10,000) Unchanged	€ 10,000 Bank debt 2025: € 10,000 Unchanged (€ 10,000) Unchanged
Balance sheet total	€ 219,044 Balance sheet total 2022: € 219,044 First fiscal year in the series	€ 205,057 Balance sheet total 2023: € 205,057 ▼ 6% vs 2022 (€ 219,044) Unchanged	€ 192,972 Balance sheet total 2024: € 192,972 ▼ 6% vs 2023 (€ 205,057) Unchanged	€ 248,919 Balance sheet total 2025: € 248,919 ▲ 29% vs 2024 (€ 192,972) Unchanged	▲ 29%

Key figures of APOTHEEK JOHAN COPPENS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to APOTHEEK JOHAN COPPENS?

What happened at APOTHEEK JOHAN COPPENS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: loss of € 41,755. Source: NBB ↗
Jan 17, 2008 New establishment in Gent. KBO
Dec 14, 2007 Start of the company according to the CBE. KBO
2007 BIMACON BV became a director. NBB
2007 Johan COPPENS became a director. NBB

In short

From € 50,818 profit in 2022 to € 41,755 loss in 2025.

Paid € 6,653 in corporate taxes since 2022.

Best year ever: 2022, with € 50,818 profit.

Paid out € 55,190 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Johan COPPENS BIMACON BV

FARMACON

BIMACON

Lo Farma

APOTHEEK JOHAN COPPENS

Behind APOTHEEK JOHAN COPPENS are Johan COPPENS and BIMACON BV. The same people are also behind FARMACON and Lo Farma. Johan COPPENS is also behind BIMACON.

Directors

According to the 2025 annual accounts

Johan COPPENS

Director

Also active at: FARMACON, BIMACON, Lo Farma

since 2007

BIMACON BV

Director · represented by Kristien BONDROIT

Also active at: FARMACON, Lo Farma

since 2007

Establishments

Establishment units

Physical locations of this company

Registered office

Antwerpsesteenweg 100

9000 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

BIMACON same network

€ 42,719 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0894.208.059
VAT number: BE 0894.208.059
Registered office: Antwerpsesteenweg 100, 9000 Gent
Names & denominations: APOTHEEK JOHAN COPPENS
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 14 December 2007
Peppol: Active · Active since 22 Mar 2024
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗